Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study

This publication has 30 references indexed in Scilit:

• Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2 Trials
  European Urology, 2013
• Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial
  The Lancet Oncology, 2012
• Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987
  Journal of Clinical Oncology, 2012
• Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer
  Journal of Clinical Oncology, 2009
• Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status
  Anti-Cancer Drugs, 2008
• Phase 2 trial of epothilone B analog BMS‐247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800)
  Cancer, 2007
• Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer
  Journal of Clinical Oncology, 2005
• A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum
  European Journal of Cancer, 1998
• Optimal two-stage designs for phase II clinical trials
  Controlled Clinical Trials, 1989
• Prediction of Creatinine Clearance from Serum Creatinine
  Nephron, 1976